|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||76.75 - 76.90|
|52 Week Range||53.76 - 80.46|
|Beta (5Y Monthly)||0.54|
|PE Ratio (TTM)||39.04|
|Forward Dividend & Yield||1.14 (1.50%)|
|Ex-Dividend Date||May 23, 2019|
|1y Target Est||54.81|
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But the truth...
EssilorLuxottica's 7.2 billion euro ($8 billion) bid for Dutch opticians group GrandVision faces a full-scale EU antitrust investigation after it declined to offer concessions to address concerns, people familiar with the matter said on Friday. EssilorLuxottica, formed last year from the merger of French lens maker Essilor and Italian eyewear group Luxottica, gave up the chance to offer concessions on Thursday, the deadline for doing so, the European Commission website showed. The new deal will give EssilorLuxottica control of more than 7,000 stores worldwide.
Today we'll take a closer look at EssilorLuxottica Société anonyme (EPA:EL) from a dividend investor's perspective...
EssilorLuxottica said it had discovered fraudulent activity at a plant in Thailand, which was expected to have a negative impact of 190 million euros ($213 million) on the spectacles company. EssilorLuxottica's shares fell by around 1 percent in early session trading, following the announcement. The group, which was formed from the merger of French lens maker Essilor and Italian eyewear group Luxottica, added that the employees suspected of involvement in the Thai fraud case had been sacked.
When EssilorLuxottica Société anonyme (ENXTPA:EL) announced its most recent earnings (30 June 2019), I did two things...
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
The big shareholder groups in EssilorLuxottica Société anonyme (EPA:EL) have power over the company. Insiders often...
Today we'll evaluate EssilorLuxottica Société anonyme (EPA:EL) to determine whether it could have potential as an...
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...
Omnicell (OMCL) aims to combine technology and innovation to enable pharmacists to expand their outreach to patients and improve services.